-
1
-
-
0034129540
-
A relationship between the evaluation of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients
-
Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S. A relationship between the evaluation of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients. J Infect Dis 2000; 181: 1523-7.
-
(2000)
J Infect Dis
, vol.181
, pp. 1523-1527
-
-
Hayashi, J.1
Furusyo, N.2
Ariyama, I.3
Sawayama, Y.4
Etoh, Y.5
Kashiwagi, S.6
-
2
-
-
0027984424
-
A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C
-
Hayashi J, Ohmiya M, Kishihara Y etal. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89: 2151-6.
-
(1994)
Am J Gastroenterol
, vol.89
, pp. 2151-2156
-
-
Hayashi, J.1
Ohmiya, M.2
Kishihara, Y.3
-
3
-
-
0032987514
-
Differences between interferon-alpha and-beta treatment for patients with chronic hepatitis C virus infection
-
Furusyo N, Hayashi J, Ohmiya M etal. Differences between interferon-alpha and-beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 1999; 44: 608-17.
-
(1999)
Dig Dis Sci
, vol.44
, pp. 608-617
-
-
Furusyo, N.1
Hayashi, J.2
Ohmiya, M.3
-
4
-
-
0031409685
-
Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis
-
Furusyo N, Hayashi J, Ueno K etal. Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clin Ther 1997; 19: 1352-67.
-
(1997)
Clin Ther
, vol.19
, pp. 1352-1367
-
-
Furusyo, N.1
Hayashi, J.2
Ueno, K.3
-
5
-
-
0346732969
-
A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development
-
Kashiwagi K, Furusyo N, Kubo N etal. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 2003; 9: 333-40.
-
(2003)
J Infect Chemother
, vol.9
, pp. 333-340
-
-
Kashiwagi, K.1
Furusyo, N.2
Kubo, N.3
-
6
-
-
0031043398
-
Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C viral infection
-
Hayashi J, Kishihara Y, Yamaji K etal. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C viral infection. Hepatology 1997; 25: 697-701.
-
(1997)
Hepatology
, vol.25
, pp. 697-701
-
-
Hayashi, J.1
Kishihara, Y.2
Yamaji, K.3
-
7
-
-
33646121757
-
Chronic hepatitis C in patients with persistently normal alanine transaminase levels
-
Shiffman ML, Diago M, Tran A etal. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4: 645-52.
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 645-652
-
-
Shiffman, M.L.1
Diago, M.2
Tran, A.3
-
8
-
-
0037008087
-
Updated definitions of healthy ranges for serum alanine aminotransferase levels
-
Prati D, Taioli E, Zanella A etal. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
-
(2002)
Ann Intern Med
, vol.137
, pp. 1-10
-
-
Prati, D.1
Taioli, E.2
Zanella, A.3
-
9
-
-
0037126675
-
Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection
-
Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-4.
-
(2002)
Ann Intern Med
, vol.137
, pp. 961-964
-
-
Alberti, A.1
Noventa, F.2
Benvegnu, L.3
Boccato, S.4
Gatta, A.5
-
10
-
-
0000427157
-
Treatment in patients with normal ALT levels. EASL International Consensus Conference on Hepatitis C: Consensus Statement
-
Tassopoulos NC. Treatment in patients with normal ALT levels. EASL International Consensus Conference on Hepatitis C: Consensus Statement. J Hepatol 1999; 30: 956-61.
-
(1999)
J Hepatol
, vol.30
, pp. 956-961
-
-
Tassopoulos, N.C.1
-
11
-
-
0030955348
-
Therapy of hepatitis C: patients with normal aminotransferase levels. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C
-
Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997; 26: 133S-6S.
-
(1997)
Hepatology
, vol.26
-
-
Marcellin, P.1
Levy, S.2
Erlinger, S.3
-
12
-
-
65449136656
-
Diagnosis, management, and treatment of hepatitis C: an update
-
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
-
(2009)
Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
Seeff, L.B.4
-
13
-
-
0035991459
-
Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC)
-
Puoti C, Castellacci R, Montagnese F etal. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37: 117-23.
-
(2002)
J Hepatol
, vol.37
, pp. 117-123
-
-
Puoti, C.1
Castellacci, R.2
Montagnese, F.3
-
14
-
-
0037126675
-
Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection
-
Alberti A, Noventa F, Benvegnù L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-4.
-
(2002)
Ann Intern Med
, vol.137
, pp. 961-964
-
-
Alberti, A.1
Noventa, F.2
Benvegnù, L.3
Boccato, S.4
Gatta, A.5
-
15
-
-
0030670088
-
Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels
-
Puoti C, Magrini A, Stati T etal. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-8.
-
(1997)
Hepatology
, vol.26
, pp. 1393-1398
-
-
Puoti, C.1
Magrini, A.2
Stati, T.3
-
16
-
-
9644262441
-
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
-
Zeuzem S, Diago M, Gane E etal. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
-
(2004)
Gastroenterology
, vol.127
, pp. 1724-1732
-
-
Zeuzem, S.1
Diago, M.2
Gane, E.3
-
17
-
-
73349108458
-
Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study
-
Puoti C, Pellicelli AM, Romano M etal. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study. Liver Int 2009; 29: 1479-84.
-
(2009)
Liver Int
, vol.29
, pp. 1479-1484
-
-
Puoti, C.1
Pellicelli, A.M.2
Romano, M.3
-
18
-
-
72949119342
-
Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France
-
Deuffic-Burban S, Babany G, Lonjon-Domanec I etal. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology 2009; 50: 1351-9.
-
(2009)
Hepatology
, vol.50
, pp. 1351-1359
-
-
Deuffic-Burban, S.1
Babany, G.2
Lonjon-Domanec, I.3
-
19
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
20
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
-
Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
-
21
-
-
78649487476
-
Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C
-
Pattullo V, Heathcote EJ, Wong DK. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int 2010; 4: 723-31.
-
(2010)
Hepatol Int
, vol.4
, pp. 723-731
-
-
Pattullo, V.1
Heathcote, E.J.2
Wong, D.K.3
-
22
-
-
33644889900
-
Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group
-
Furusyo N, Katoh M, Tanabe Y etal. Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. World J Gastroenterol 2006; 12: 784-90.
-
(2006)
World J Gastroenterol
, vol.12
, pp. 784-790
-
-
Furusyo, N.1
Katoh, M.2
Tanabe, Y.3
-
23
-
-
47649095345
-
Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group
-
Furusyo N, Kajiwara E, Takahashi K etal. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol 2008; 23: 1094-104.
-
(2008)
J Gastroenterol Hepatol
, vol.23
, pp. 1094-1104
-
-
Furusyo, N.1
Kajiwara, E.2
Takahashi, K.3
-
24
-
-
35548933202
-
Detection and quantitation of HCV RNA using real-time PCR after automated sample processing
-
Sandres-Sauné K, Abravanel F, Nicot F etal. Detection and quantitation of HCV RNA using real-time PCR after automated sample processing. J Med Virol 2007; 79: 1821-6.
-
(2007)
J Med Virol
, vol.79
, pp. 1821-1826
-
-
Sandres-Sauné, K.1
Abravanel, F.2
Nicot, F.3
-
25
-
-
33947133809
-
Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system
-
Sizmann D, Boeck C, Boelter J etal. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007; 38: 326-33.
-
(2007)
J Clin Virol
, vol.38
, pp. 326-333
-
-
Sizmann, D.1
Boeck, C.2
Boelter, J.3
-
26
-
-
79954620612
-
Ribavirin concentration in the later stages of 48week pegylated interferon-α2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response
-
Furusyo N, Murata M, Ogawa E etal. Ribavirin concentration in the later stages of 48week pegylated interferon-α2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. J Antimicrob Chemother 2011; 66: 1127-39.
-
(2011)
J Antimicrob Chemother
, vol.66
, pp. 1127-1139
-
-
Furusyo, N.1
Murata, M.2
Ogawa, E.3
-
27
-
-
68749109781
-
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin
-
Hiramatsu N, Oze T, Yakushijin T etal. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat 2009; 16: 586-94.
-
(2009)
J Viral Hepat
, vol.16
, pp. 586-594
-
-
Hiramatsu, N.1
Oze, T.2
Yakushijin, T.3
-
28
-
-
77957585975
-
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
-
Kainuma M, Furusyo N, Kajiwara E etal. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16: 4400-9.
-
(2010)
World J Gastroenterol
, vol.16
, pp. 4400-4409
-
-
Kainuma, M.1
Furusyo, N.2
Kajiwara, E.3
-
29
-
-
36549058800
-
Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts
-
Okanoue T, Itoh Y, Minami M etal. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res 2008; 38: 27-36.
-
(2008)
Hepatol Res
, vol.38
, pp. 27-36
-
-
Okanoue, T.1
Itoh, Y.2
Minami, M.3
-
30
-
-
77951701962
-
Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection
-
Hsu CS, Liu CH, Liu CJ etal. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. J Gastroenterol Hepatol 2010; 25: 970-7.
-
(2010)
J Gastroenterol Hepatol
, vol.25
, pp. 970-977
-
-
Hsu, C.S.1
Liu, C.H.2
Liu, C.J.3
-
31
-
-
79952651309
-
Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort
-
Ramcharran D, Wahed AS, Conjeevaram HS etal. Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort. J Viral Hepat 2011; 18: 144-52.
-
(2011)
J Viral Hepat
, vol.18
, pp. 144-152
-
-
Ramcharran, D.1
Wahed, A.S.2
Conjeevaram, H.S.3
-
32
-
-
0031891214
-
Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study
-
Sangiovanni A, Morales R, Spinzi G etal. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998; 27: 853-6.
-
(1998)
Hepatology
, vol.27
, pp. 853-856
-
-
Sangiovanni, A.1
Morales, R.2
Spinzi, G.3
-
33
-
-
0033659668
-
Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?
-
Puoti C, Castellacci R, Montagnese F. Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? Dig Liver Dis 2000; 32: 634-43.
-
(2000)
Dig Liver Dis
, vol.32
, pp. 634-643
-
-
Puoti, C.1
Castellacci, R.2
Montagnese, F.3
-
34
-
-
0033731762
-
Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels
-
Ohmiya M, Hayashi J, Ueno K etal. Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels. Dig Dis Sci 2000; 45: 1953-8.
-
(2000)
Dig Dis Sci
, vol.45
, pp. 1953-1958
-
-
Ohmiya, M.1
Hayashi, J.2
Ueno, K.3
-
35
-
-
72949123800
-
Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease?
-
Lawson A. Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease? J Viral Hepat 2010; 17: 51-8.
-
(2010)
J Viral Hepat
, vol.17
, pp. 51-58
-
-
Lawson, A.1
|